NCT03678883 2024-11-079-ING-41 in Patients with Advanced CancersActuate Therapeutics Inc.Phase 2 Active not recruiting350 enrolled
NCT03435250 2024-07-25Study of AG-270 in Participants With Advanced Solid Tumors or Lymphoma With MTAP LossServierPhase 1 Terminated123 enrolled
NCT03878524 2024-03-04Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialOHSU Knight Cancer InstitutePhase 1 Terminated2 enrolled
NCT05631886 2023-08-28Combination of CAR-DC Vaccine and ICIs in Malignant TumorsChinese PLA General HospitalPhase 1 Recruiting10 enrolled
NCT03003546 2023-06-15Nab-paclitaxel/Rituximab-coated Nanoparticle AR160 in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma, LS1681 TrialMayo ClinicPhase 1 Completed9 enrolled
NCT02376699 2023-05-01Safety Study of SEA-CD40 in Cancer PatientsSeagen Inc.Phase 1 Terminated159 enrolled
NCT01929941 2018-01-17An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced MalignanciesIncyte CorporationPhase 1 Terminated5 enrolled
NCT01555853 2016-12-06Phase I/II Study of Abraxane in Recurrent and Refractory LymphomaWashington University School of MedicinePhase 1 Terminated20 enrolled